贝美药业

Bemei Pharmaceutical is a specialty pharmaceutical company headquartered in Shenzhen, China, focused exclusively on the pediatric healthcare market. Established in 2017, the company addresses the critical shortage of child-specific medications in China through a combination of internal R&D and strategic global licensing. Bemei's product portfolio spans multiple therapeutic areas, including respiratory, anti-infective, digestive, and nervous system disorders, with a focus on patient-friendly formulations like dry suspensions and oral solutions. The company has successfully commercialized several key products, such as oseltamivir phosphate dry suspension, and maintains a robust pipeline of over 30 programs. Backed by top-tier investors like Hillhouse Capital, Bemei is positioned as a leader in the modernization of pediatric medicine in China.